Bioeq IP

Bioeq AG is a private, commercial-stage biosimilar company operating as a joint venture between Polpharma Biologics and Formycon AG. The company employs a capital-efficient, asset-light model, developing biosimilars and out-licensing them to established international pharmaceutical partners for distribution in numerous countries. With at least one product already on the market in multiple regions, Bioeq is positioned to capitalize on the growing global demand for affordable biologic medicines while navigating a complex regulatory and competitive landscape.

Biosimilar development platform leveraging analytical characterization, process development, and comparability studies, supported by parent companies' manufacturing and R&D capabilities.

Bioeq competes in the crowded global biosimilar market against large, integrated generics firms (e.g., Sandoz, Viatris), other biosimilar specialists (e.g., Celltrion, Samsung Bioepis), and the originator companies themselves. Its differentiation lies in its focused, partnership-driven model and the combined technical expertise of its parent companies.